Roth Capital Partners downgraded NovaBay Pharmaceuticals (NYSE American:NBY) to “neutral” from “buy” and lowered its price target to $4 from $5, pending renewed prescription growth for the eyelid hygiene treatment...
Paradigm Capital raised its price target for Profound Medical (TSXV:PRN) to $3 from $2.25 after the company completed an upsized equity financing of $34.5-million. The stock closed at $1.05 on March 20. “We see this...
Profound Medical (TSXV:PRN) closed a previously announced bought deal financing for gross proceeds of $34.5-million, including the exercise of the underwriters’ over-allotment option. Net proceeds are expected to be...
Maxim Group upgraded Sellas Life Sciences (NASDAQ:SLS) to “buy” from “hold,” with a $13 price target after meeting with Sellas management. The stock closed at $4.79 on March 16. Sellas completed a merger with Galena...
Piper Jaffray upgraded Nuvectra (NASDAQ:NVTR) to “overweight” from “neutral” and raised its price target to $16 from $12 after the company reported fourth quarter results. The stock closed at $11.69 on March 15. The...
VolitionRx (NYSE American:VNRX) closed an offering of 3.5 million common shares at a price of $2.40 a share for gross proceeds of $8.4-million. Volition, which develops blood tests to help diagnose a range of cancers...
Mackie Research Capital initiated coverage of Acerus Pharmaceuticals (TSX:ASP) with a “speculative buy” rating and a 12-month target price of 50 cents. The stock closed at 26 cents on March 13. Acerus specializes in men...
Piper Jaffray initiated coverage of Motus GI Holdings (NASDAQ:MOTS) with an “overweight” rating and $7 price target. The stock closed at $4.98 on March 9. The company’s Pure-Vu device makes the prep regimen for...
Maxim Group downgraded Can-Fite Biopharma (NYSE American:CANF) to “hold” from “buy” and removed its previous $7 price target after the company announced a $5-million registered direct offering. The stock was quoted at...
Roth Capital Partners doubled its price target for Juniper Pharmaceuticals (NASDAQ:JNP) to $24 from $12 after the company reported 2017 results. The stock closed at $10 on March 9. Juniper is focused on developing...